Evidence map›Paper›PMID 30092762›Full record

ArticleBMC genomics2018

Whole genome analyses of CMY-2-producing Escherichia coli isolates from humans, animals and food in Germany.

Michael Pietsch, Alexandra Irrgang, Nicole Roschanski, Geovana Brenner Michael, Axel Hamprecht, Heime Rieber, Annemarie Käsbohrer, Stefan Schwarz, Uwe Rösler, Lothar Kreienbrock and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 167 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Avian PathogenicVeterinary sciences · 2025
    Review
  9. Article
  10. Association of DiarrheagenicMicroorganisms · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Comparison of IncK-Antibiotics (Basel, Switzerland) · 2024
    Article
  18. Antimicrobial agents and chemotherapy · 2024
    Review
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Michael PietschRobert Koch-Institute, FG 13 Nosocomial Pathogens and Antibiotic Resistance, Burgstr, 37 38855, Wernigerode, Germany.
Alexandra IrrgangDepartment of Biological Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Nicole RoschanskiFreie Universität Berlin, Institute for Animal Hygiene and Environmental Health, Berlin, Germany.
Geovana Brenner MichaelInstitute of Microbiology and Epizootics, Freie Universität Berlin, Berlin, Germany.
Axel HamprechtInstitute for Medical Microbiology, Immunology and Hygiene, University of Cologne, University Hospital Cologne, Cologne, Germany.
Heime RieberMedizinisches Versorgungszentrum Dr. Stein, Division of Microbiology, Mönchengladbach, Germany.
Annemarie KäsbohrerDepartment of Biological Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Stefan SchwarzInstitute of Microbiology and Epizootics, Freie Universität Berlin, Berlin, Germany.
Uwe RöslerFreie Universität Berlin, Institute for Animal Hygiene and Environmental Health, Berlin, Germany.
Lothar KreienbrockInstitute for Biometrics, Epidemiology and Data Processing, University of Veterinary Medicine, Hanover, Germany.
Yvonne PfeiferRobert Koch-Institute, FG 13 Nosocomial Pathogens and Antibiotic Resistance, Burgstr, 37 38855, Wernigerode, Germany.
Stephan FuchsRobert Koch-Institute, FG 13 Nosocomial Pathogens and Antibiotic Resistance, Burgstr, 37 38855, Wernigerode, Germany.
Guido WernerRobert Koch-Institute, FG 13 Nosocomial Pathogens and Antibiotic Resistance, Burgstr, 37 38855, Wernigerode, Germany. wernerg@rki.de.
RESET Study Group
Robert Koch Institute · DEFriedrich-Loeffler-Institut · DEFederal Institute for Risk Assessment · DEUniversity of Veterinary Medicine Hannover, Foundation · DEUniversity of Cologne · DE

Funding

Bundesministerium für Bildung und Forschung 01KI1313
6 · The paper itself

Abstract

backgroundResistance to 3rd-generation cephalosporins in Escherichia coli is mostly mediated by extended-spectrum beta-lactamases (ESBLs) or AmpC beta-lactamases. Besides overexpression of the species-specific chromosomal ampC gene, acquisition of plasmid-encoded ampC genes, e.g. bla

resultsThe data of the 164 sequenced isolates revealed 59 different sequence types (STs); the most prevalent ones were ST38 (n = 19), ST131 (n = 16) and ST117 (n = 13). Two STs were present in all reservoirs: ST131 (human n = 8; food n = 2; animal n = 6) and ST38 (human n = 3; animal n = 9; food n = 7). All but one CMY-2-producing ST131 isolates belonged to the clade B (fimH22) that differed substantially from the worldwide dominant CTX-M-15-producing clonal lineage ST131-O25b clade C (fimH30). Plasmid replicon types IncI1 (n = 61) and IncK (n = 72) were identified for the majority of bla

conclusionWe found isolates of distinct E. coli clonal lineages (ST131 and ST38) in all three reservoirs. However, a direct clonal relationship of isolates from food animals and humans was only noticeable for a few cases. The CMY-2-producing E. coli-ST131 represents a clonal lineage different from the CTX-M-15-producing ST131-O25b cluster. Apart from the ST-driven spread, plasmid-mediated spread, especially via IncI1 and IncK plasmids, likely plays an important role for emergence and transmission of bla

Indexed as

Animalsbeta-LactamasesCattleChickensEscherichia coliEscherichia coli InfectionsEscherichia coli ProteinsFood AnalysisGermanyPhylogenyPolymorphism, Single NucleotideSwineTurkeysWhole Genome Sequencingbeta-lactamase CMY-2, E colibeta-LactamasesEscherichia coli ProteinsAmpC beta-lactamaseFood chainMultidrug-resistantPlasmid

Identifiers

PMID30092762
PMCPMC6085623
OpenAlexW2887830081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.